BACKGROUND: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tissue in liver biopsies by measuring the amount of collagen deposition as a proportion of the total biopsy area. CPA predicts clinical outcomes in patients with HCV and can sub-classify cirrhosis. AIM: To test the ability of CPA to quantify fibrosis and predict clinical outcomes in patients with NAFLD. METHODS: We assessed consecutive patients with biopsy-proven NAFLD from three European centres. Clinical and laboratory data were collected at baseline and at the time of the last clinical follow-up or death. CPA was performed at two different objective magnifications, whole biopsy macro and ×4 objective magnification, named standard (SM) and high (HM) magnification respectively. The correlation between CPA and liver stiffness was assessed in a sub-group of patients. RESULTS: Of 437 patients, 32 (7.3%) decompensated and/or died from liver-related causes during a median follow-up of 103 months. CPA correlated with liver stiffness and liver fibrosis stage across the whole spectrum of fibrosis. HM CPA was significantly higher than SM CPA in stages F0-F3 but similar in cirrhosis, reflecting a higher ability to capture pericellular/perisinusoidal fibrosis at early stages. Age at baseline (HR: 1.04, 95% CI: 1.01-1.08), HM CPA (HR: 1.04 per 1% increase, 95% CI: 1.01-1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI: 5.02-47.84) were independent predictors of liver-related clinical outcomes at standard and competing risk multivariate Cox-regression analysis. CONCLUSIONS: CPA accurately measures fibrosis and is an independent predictor of clinical outcomes in NAFLD; hence it merits further evaluation as a surrogate endpoint in clinical trials.
BACKGROUND: Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tissue in liver biopsies by measuring the amount of collagen deposition as a proportion of the total biopsy area. CPA predicts clinical outcomes in patients with HCV and can sub-classify cirrhosis. AIM: To test the ability of CPA to quantify fibrosis and predict clinical outcomes in patients with NAFLD. METHODS: We assessed consecutive patients with biopsy-proven NAFLD from three European centres. Clinical and laboratory data were collected at baseline and at the time of the last clinical follow-up or death. CPA was performed at two different objective magnifications, whole biopsy macro and ×4 objective magnification, named standard (SM) and high (HM) magnification respectively. The correlation between CPA and liver stiffness was assessed in a sub-group of patients. RESULTS: Of 437 patients, 32 (7.3%) decompensated and/or died from liver-related causes during a median follow-up of 103 months. CPA correlated with liver stiffness and liver fibrosis stage across the whole spectrum of fibrosis. HM CPA was significantly higher than SM CPA in stages F0-F3 but similar in cirrhosis, reflecting a higher ability to capture pericellular/perisinusoidal fibrosis at early stages. Age at baseline (HR: 1.04, 95% CI: 1.01-1.08), HM CPA (HR: 1.04 per 1% increase, 95% CI: 1.01-1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI: 5.02-47.84) were independent predictors of liver-related clinical outcomes at standard and competing risk multivariate Cox-regression analysis. CONCLUSIONS:CPA accurately measures fibrosis and is an independent predictor of clinical outcomes in NAFLD; hence it merits further evaluation as a surrogate endpoint in clinical trials.
Authors: Iris Y Zhou; Veronica Clavijo Jordan; Nicholas J Rotile; Eman Akam; Smitha Krishnan; Gunisha Arora; Hema Krishnan; Hannah Slattery; Noah Warner; Nathaniel Mercaldo; Christian T Farrar; Jeremy Wellen; Robert Martinez; Franklin Schlerman; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan Journal: Radiology Date: 2020-04-28 Impact factor: 11.105
Authors: Rish K Pai; David E Kleiner; John Hart; Oyedele A Adeyi; Andrew D Clouston; Cynthia A Behling; Dhanpat Jain; Sanjay Kakar; Mayur Brahmania; Lawrence Burgart; Kenneth P Batts; Mark A Valasek; Michael S Torbenson; Maha Guindi; Hanlin L Wang; Veeral Ajmera; Leon A Adams; Claire E Parker; Brian G Feagan; Rohit Loomba; Vipul Jairath Journal: Aliment Pharmacol Ther Date: 2019-10-03 Impact factor: 8.171
Authors: James B Maurice; Robert Goldin; Andrew Hall; Jennifer C Price; Giada Sebastiani; Caryn G Morse; Laura Iogna Prat; Hugo Perazzo; Lucy Garvey; Patrick Ingiliz; Giovanni Guaraldi; Emmanouil Tsochatzis; Maud Lemoine Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Philipp Königshofer; Benedikt Silvester Hofer; Ksenia Brusilovskaya; Benedikt Simbrunner; Oleksandr Petrenko; Katharina Wöran; Merima Herac; Judith Stift; Katharina Lampichler; Gerald Timelthaler; David Bauer; Lukas Hartl; Bernhard Robl; Maria Sibila; Bruno K Podesser; Georg Oberhuber; Philipp Schwabl; Mattias Mandorfer; Michael Trauner; Thomas Reiberger Journal: Hepatology Date: 2021-12-20 Impact factor: 17.298
Authors: M Lunova; S Frankova; H Gottfriedova; R Senkerikova; M Neroldova; J Kovac; E Kieslichova; V Lanska; E Sticova; J Spicak; M Jirsa; J Sperl Journal: Physiol Res Date: 2021-06-01 Impact factor: 1.881
Authors: Roberta Forlano; Benjamin H Mullish; Nikolaos Giannakeas; James B Maurice; Napat Angkathunyakul; Josephine Lloyd; Alexandros T Tzallas; Markos Tsipouras; Michael Yee; Mark R Thursz; Robert D Goldin; Pinelopi Manousou Journal: Clin Gastroenterol Hepatol Date: 2019-12-27 Impact factor: 11.382
Authors: David Marti-Aguado; Matías Fernández-Patón; Clara Alfaro-Cervello; Claudia Mestre-Alagarda; Mónica Bauza; Ana Gallen-Peris; Víctor Merino; Salvador Benlloch; Judith Pérez-Rojas; Antonio Ferrández; Víctor Puglia; Marta Gimeno-Torres; Victoria Aguilera; Cristina Monton; Desamparados Escudero-García; Ángel Alberich-Bayarri; Miguel A Serra; Luis Marti-Bonmati Journal: Biomolecules Date: 2021-12-02